Four-year Biktarvy data presented at IAS 2021 demonstrate high efficacy and durable viral suppression in treatment-naïve adults with HIV – Gilead Sciences
Gilead Sciences, Inc. announced a pooled analysis of a 48-week open-label extension of two Phase III studies (Study 1489 and Study 1490) shows 99% of participants who initiated… read more.